No abstract
Background: In the European Member States, the systems for pharmaceutical pricing and reimbursement differ significantly. Amongst the administration and policy-makers at both national and European levels there is a lot of interest in the different pharmaceutical systems of the Member States as a means of learning from their experiences in pricing and reimbursement. Objectives: The general objective of the PPRI–Project – started in April 2005 - is to develop a network of authorities and institutions in order to improve information and knowledge on the pharmaceutical systems in the enlarged European Union. This network should facilitate a regular exchange of information and allow a process of learning from each other. Project description: The PPRI project team consists of the main partner (ÖBIG), an associated partner (WHOEURO) and a network of partners and observers which represent national stakeholders from almost all EU Member States and a number of international stakeholders. The information on pharmaceutical pricing and reimbursement will be collected and summarised in country reports (“Pharma Profiles”) which follow a homogenous structure. The individual country’s information will be analysed and compared on the basis of a set of indicators (benchmarks). Deliverables:The main deliverables of the project are: • Pharma Profiles, • a benchmarking report, in which pharmaceutical pricing and reimbursement in the Member States is compared, • a website containing information on the project and on pricing and reimbursement in the Member States, and • a conference at the end of the project during which the study results will be disseminated.
Medicines account for an increasing proportion of healthcare budgets in all European countries. The EuroMedStat project aims to establish methods and systems for comparing the publicly funded pharmaceutical markets across Europe. A key issue is how to compare prices across countries. There are established methods for bilateral comparisons between two countries which are used in pricing negotiations but no means of a broader overview. Difficulties exist because of: a lack of directly comparable packages of individual medicines across Europe; currency conversion in some countries, despite the use of the euro; a range of different prices from different parts of the supply chain that could be studied; differences even within what are included in prices across countries (e.g. pharmacy fees etc); and most important, lack of availability of data on many of these points. Our aim was to produce pragmatic suggestions and these are presented. We suggest that the price used in the pharmacy retail price; that the denominator for price is the defined daily dose; and that the package size selected is that which most closely equates to one month’s treatment at the most commonly used dosage. From this, we derive a number of markers of the efficiency of national markets. It is important that the limitations of these are understood and that they are sued only as broad indicators to begin exploring areas of possible concern, and not for instance in price setting. These indicators now need field testing and the project will extent to include the new accession countries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.